Medical Developments Financials
MVP Stock | 0.42 0.01 2.33% |
Operating Margin (0.15) | Profit Margin (1.24) | Return On Equity (0.65) |
Medical | Select Account or Indicator |
Understanding current and past Medical Developments Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Medical Developments' financial statements are interrelated, with each one affecting the others. For example, an increase in Medical Developments' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Medical Developments' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Medical Developments International. Check Medical Developments' Beneish M Score to see the likelihood of Medical Developments' management manipulating its earnings.
Medical Developments Stock Summary
Medical Developments competes with Autosports, Cleanaway Waste, Step One, AiMedia Technologies, and Aristocrat Leisure. Medical Developments is entity of Australia. It is traded as Stock on AU exchange.Foreign Associates | |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Instrument | Australia Stock View All |
Exchange | Australian Securities Exchange |
ISIN | AU000000MVP2 |
Business Address | 4 Caribbean Drive, |
Sector | Pharmaceuticals |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | medicaldev.com |
Phone | 61 3 9547 1888 |
You should never invest in Medical Developments without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Medical Stock, because this is throwing your money away. Analyzing the key information contained in Medical Developments' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Medical Developments Key Financial Ratios
Medical Developments' financial ratios allow both analysts and investors to convert raw data from Medical Developments' financial statements into concise, actionable information that can be used to evaluate the performance of Medical Developments over time and compare it to other companies across industries.Revenue | 33.15 M | ||||
Gross Profit | 22.21 M | ||||
EBITDA | (29.45 M) | ||||
Net Income | (40.99 M) | ||||
Cash And Equivalents | 24.66 M |
Medical Developments Key Balance Sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 94.9M | 100.2M | 101.4M | 109.5M | 59.2M | 44.3M | |
Net Debt | (12.2M) | (33.2M) | (17.6M) | (22.1M) | (7.4M) | (7.8M) | |
Accounts Payable | 3.8M | 3.3M | 9.4M | 13.3M | 8.3M | 8.7M | |
Cash | 15.5M | 36.3M | 20.4M | 24.7M | 9.7M | 7.9M | |
Net Receivables | 4.1M | 5.0M | 6.2M | 8.9M | 7.1M | 7.4M | |
Inventory | 5.9M | 5.7M | 7.1M | 8.4M | 8.8M | 9.2M | |
Other Current Assets | 416K | 397K | 620K | 791K | 565K | 482.7K | |
Total Liab | 51.5M | 31.9M | 44.1M | 28.2M | 13.4M | 16.1M | |
Total Current Assets | 26.0M | 47.4M | 34.4M | 42.8M | 26.1M | 15.1M | |
Short Term Debt | 417K | 337K | 348K | 352K | 371K | 494.4K | |
Intangible Assets | 16.1M | 8.2M | 8.0M | 8.5M | 19.0M | 20.0M | |
Common Stock | 41.0M | 76.9M | 77.0M | 105.7M | 121.6M | 127.7M | |
Other Current Liab | 4.0M | 3.3M | 683K | 1.6M | 639K | 607.1K | |
Other Liab | 30.3M | 22.2M | 22.0M | 2.2M | 2.6M | 2.4M | |
Retained Earnings | 427K | (12.1M) | (24.5M) | (30.2M) | (62.9M) | (59.7M) | |
Other Assets | 36.0M | 35.1M | 40.7M | 8.1M | 4.6M | 4.4M | |
Net Tangible Assets | 32.3M | 62.3M | 51.7M | 75.7M | 87.1M | 91.4M | |
Long Term Debt Total | 2.9M | 2.7M | 2.5M | 2.2M | 2.5M | 2.6M | |
Net Invested Capital | 43.4M | 68.3M | 57.3M | 81.3M | 45.7M | 54.1M |
Medical Developments Key Income Statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Interest Expense | 114K | 121K | 103K | 95K | 86K | 78.2K | |
Total Revenue | 22.5M | 25.3M | 21.9M | 32.3M | 33.1M | 34.8M | |
Gross Profit | 13.7M | 16.7M | (3.1M) | (2.5M) | (2.5M) | (2.4M) | |
Operating Income | 1.9M | (5.2M) | (15.7M) | (20.3M) | (16.9M) | (16.0M) | |
Ebit | 435K | (14.9M) | (15.8M) | (7.4M) | (32.8M) | (31.2M) | |
Ebitda | 3.0M | (11.1M) | (12.9M) | (4.3M) | (29.4M) | (28.0M) | |
Income Before Tax | 321K | (15.0M) | (15.9M) | (7.5M) | (32.9M) | (31.3M) | |
Income Tax Expense | (58K) | (2.4M) | (3.5M) | (1.9M) | 8.1M | 8.5M | |
Cost Of Revenue | 8.8M | 8.6M | 25.0M | 34.9M | 35.6M | 37.4M | |
Net Income | 379K | (12.6M) | (12.4M) | (5.6M) | (41.0M) | (38.9M) | |
Research Development | 396K | 536K | 220K | 236K | 271.4K | 195.6K | |
Tax Provision | (58K) | (2.4M) | (3.5M) | (1.9M) | 8.1M | 8.5M | |
Net Interest Income | (114K) | (50K) | (58K) | 562K | 316K | 331.8K | |
Interest Income | 336K | 71K | 45K | 657K | 402K | 243.6K |
Medical Developments Key Cash Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Change In Cash | (10.1M) | 20.7M | (15.9M) | 4.3M | (14.9M) | (14.2M) | |
Free Cash Flow | (8.7M) | (15.4M) | (15.9M) | (24.2M) | (13.9M) | (13.3M) | |
Depreciation | 1.5M | 3.7M | 2.9M | 3.1M | 3.4M | 3.6M | |
Other Non Cash Items | (1.7M) | 8.9M | 9.8M | (5.4M) | 22.6M | 23.8M | |
Capital Expenditures | 8.9M | 6.6M | 5.2M | 7.7M | 3.2M | 2.5M | |
Net Income | 379K | (12.6M) | (12.4M) | (5.6M) | (41.0M) | (38.9M) | |
End Period Cash Flow | 15.5M | 36.3M | 20.4M | 24.7M | 9.7M | 8.2M | |
Dividends Paid | 2.1M | 35.5M | 139K | 26.4M | 30.3M | 31.9M | |
Change To Inventory | (2.8M) | 154K | (1.4M) | (1.8M) | (393K) | (412.7K) | |
Net Borrowings | (288K) | (232K) | (215K) | (253K) | (227.7K) | (239.1K) | |
Change To Netincome | (2.6M) | 7.5M | 1.7M | (12.1M) | (10.9M) | (10.3M) | |
Investments | (8.5M) | (6.5M) | (5.2M) | (7.1M) | (3.2M) | (3.3M) |
Medical Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Medical Developments's current stock value. Our valuation model uses many indicators to compare Medical Developments value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Medical Developments competition to find correlations between indicators driving Medical Developments's intrinsic value. More Info.Medical Developments International is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Medical Developments' earnings, one of the primary drivers of an investment's value.Medical Developments Systematic Risk
Medical Developments' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Medical Developments volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was three with a total number of output elements of fifty-eight. The Beta measures systematic risk based on how returns on Medical Developments correlated with the market. If Beta is less than 0 Medical Developments generally moves in the opposite direction as compared to the market. If Medical Developments Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Medical Developments is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Medical Developments is generally in the same direction as the market. If Beta > 1 Medical Developments moves generally in the same direction as, but more than the movement of the benchmark.
Medical Developments International Total Assets Over Time
Medical Developments Thematic Clasifications
Medical Developments International is part of Drugs investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Drug manufacturing and delivery. Companies involved in medical and pharmaceutical drug research, manufacturing, and delivery
This theme covers Drug manufacturing and delivery. Companies involved in medical and pharmaceutical drug research, manufacturing, and delivery. Get More Thematic Ideas
Drugs | View |
Medical Developments November 23, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Medical Developments help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Medical Developments International. We use our internally-developed statistical techniques to arrive at the intrinsic value of Medical Developments International based on widely used predictive technical indicators. In general, we focus on analyzing Medical Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Medical Developments's daily price indicators and compare them against related drivers.
Information Ratio | (0.04) | |||
Maximum Drawdown | 22.83 | |||
Value At Risk | (4.44) | |||
Potential Upside | 4.55 |
Additional Tools for Medical Stock Analysis
When running Medical Developments' price analysis, check to measure Medical Developments' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medical Developments is operating at the current time. Most of Medical Developments' value examination focuses on studying past and present price action to predict the probability of Medical Developments' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medical Developments' price. Additionally, you may evaluate how the addition of Medical Developments to your portfolios can decrease your overall portfolio volatility.